MESS-study MRSA Eradication Study Skåne

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-01

Study Completion Date

2015-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

NCT00711854

MRSA Infection

COMPLETED PHASE4

Optimal Treatment of MRSA Throat Carriers

NCT04104178

MRSA MRSA Colonization

COMPLETED PHASE3

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827

Cystic Fibrosis

COMPLETED PHASE2

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540

Skin Infections, Bacterial

COMPLETED PHASE3

Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization

NCT01438515

Methicillin-resistant Staphylococcus Aureus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Throatcarriers of MRSA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mupirocin

Topical treatment

Group Type ACTIVE_COMPARATOR

Mupirocin

Intervention Type DRUG

Topical in the nose 3 times daily for 5 days

Rifampin+Clindamycine or Trimehoprimsulfa

Intervention Type DRUG

Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

Rifampicin+Clindamycine or Trimethoprimsulfa

Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2

Group Type ACTIVE_COMPARATOR

Rifampin+Clindamycine or Trimehoprimsulfa

Intervention Type DRUG

Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mupirocin

Topical in the nose 3 times daily for 5 days

Intervention Type DRUG

Rifampin+Clindamycine or Trimehoprimsulfa

Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion Criteria

Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

Minimum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No